Last Update: Aug 25, 2026 Patients' Preferences for Primary Immune Thrombocytopenia Treatment ClinicalTrials.gov Identifier: [NCT07786077](https://clinicaltrials.gov/ct2/show/NCT07786077) Novartis Reference Number:CVAY736Q12001 [See if you Pre-qualify](#trial-eligibility "See if you Pre-qualify") All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. ## Study Description This study aims to evaluate treatment preferences of patients with Primary Immune Thrombocytopenia (ITP) in the United States (US) by conducting a preference elicitation survey. This is a non-interventional study to assess treatment preferences from patients with ITP. Data will be collected from participants using a preference elicitation survey. The study consists of two stages. Stage 1 includes the development of the survey and identification of key treatment attributes. Stage 2 involves administration of the finalized survey, followed by comprehensive analysis of the data to assess treatment preferences. Condition Primary Immune Thrombocytopenia Overall Status Recruiting Number of Participants100 Start Date Dec 08, 2025 Completion Date Dec 15, 2026 Gender All Age(s) 18 Years - (Adult, Older Adult) ## Eligibility Criteria Inclusion criteria: 1\. Currently living in the US. 2\. Aged 18 years and older on the day of providing informed consent. 3\. A diagnosis of primary ITP: a. For participants receiving first-line (1L) treatment for ITP: i. Diagnosed with primary ITP and started 1L corticosteroids within 3 months of diagnosis ii. Responded to 1L corticosteroid treatment \\\[with or without intravenous immunoglobulin (IVIg)\\\] b. For participants receiving second-line (2L) treatment for ITP: i. Assessed as needing or are taking thrombopoietin receptor agonist (TPO-RA) treatment for 2L treatment ii. Has previously been treated with a 1L corticosteroid (with or without IVIg) with insufficient response or relapse Exclusion criteria: 1\. For participants receiving 1L treatment for ITP only: Previous or current use of treatments different from corticosteroids and/or IVIg/anti-D immunoglobulin. 2\. For participants receiving 2L ITP treatment: Previous or current use of treatments different from corticosteroids, IVIg/anti-D immunoglobulin or one TPO-RA (i.e. patients who have used any treatment in a third-line setting are ineligible). United States #### Novartis Recruiting East Hanover,New Jersey,07936,United States ## Worldwide Contacts If the location of your choosing does not feature any contact detail, please reach out using the information below. #### Novartis Pharmaceuticals Phone: [ +41613241111](tel:+41613241111) Email: